###### Strengths and limitations of this study

This study for the first time highlights a novel factor which can be altered or improved so as to relieve psychological disturbance and improve the quality of life of patients with glaucoma.Strengths of the study include the large sample with a high participation rate, control of confounding variables, and the use of several questionnaires.The main weakness of the study is that it is hospital-based rather than population-based.

Introduction {#s1}
============

Glaucoma is the second leading cause of blindness globally, after cataracts. However, because the blindness it causes is irreversible, glaucoma presents perhaps an even greater public health challenge than cataracts.[@R1] Due to its asymptomatic, lifelong, chronic nature and potential outcome of blindness, it can often impose a psychological burden on patients.[@R2] [@R3] Anxiety and depression are two common forms of psychological disturbance and previous studies have shown that patients with glaucoma have a greater likelihood of having these conditions.[@R4] Younger age, being female and having a moderate or heavy economic burden are risk factors for anxiety, while older age, increasing severity and duration of glaucoma are risk factors for depression.[@R7] [@R8] However, all these factors are objective and/or slow to change. Until now, to the best of our knowledge, few subjective factors have been shown to be associated with psychological disturbance in patients with glaucoma. In contrast to objective factors, subjective factors can change or be regulated. Thus, addressing subjective factors might alleviate the anxiety and depression of patients with glaucoma.

The term 'quality of life' (QoL) is a broad concept incorporating the patient\'s perspective of his or her health; it also reflects the gap between a person\'s expectations and their present status.[@R9] QoL was introduced to ophthalmology in the 1980s as an evaluation indicator. Compared with the general QoL evaluation tools, vision-related QoL measurements have been widely accepted as specifically reflecting the impact of visual function impairment on the individual.[@R10] Maximising a patient\'s QoL has been one of the main goals of glaucoma treatment,[@R11] since vision-related QoL is reduced by the condition.[@R12] [@R13] Previous studies on the factors influencing vision-related QoL among patients with glaucoma have focused mainly on clinical types, visual function,[@R14] [@R15] treatment regimen and self-management.[@R16] However, there have been no studies on how to improve QoL among patients with glaucoma, and many unknown factors have yet to be explored.

Ignorance of the nature of illness can delay or prevent compliance with the treatment of many diseases including glaucoma,[@R17] and poor adherence to treatment may lead to preventable vision loss. It has been reported that over half of the undiagnosed cases of glaucoma in the general population occur in regions with high medical standards.[@R20] For those who had been diagnosed with glaucoma, over a third did not know or were not sure of their glaucoma type.[@R21] Thus, it is important to improve understanding of glaucoma in patients with the condition. However, how to increase the understanding and knowledge of patients remains a problem. Education of patients might be an easy and effective solution. The Shanghai Glaucoma Club (SGC) has attempted to educate patients for more than 16 years.[@R21] [@R22] A previous study showed that club members had a better understanding of glaucoma and looked 'happier' than general patients.[@R21] This suggests possible relationships between understanding of glaucoma and anxiety, depression and QoL. Therefore, this study aims to determine if level of understanding of glaucoma is associated with psychological disturbance and vision-related QoL in patients with glaucoma. Evidence of such relationships might suggest a way to alleviate psychological disturbance and enhance QoL among patients with glaucoma, which would be of great significance in the treatment of glaucoma.

Methods {#s2}
=======

Subjects {#s2a}
--------

This prospective study enrolled patients with clinically diagnosed glaucoma who were scheduled for vision care at the Department of Ophthalmology of the Shanghai Eye, Ear, Nose, and Throat Hospital of Fudan University from July 2012 to November 2012. The inclusion criteria were Chinese-speaking adult patients (18 years old and above) with a glaucoma diagnosis based on typical glaucomatous cupping of the optic disc with compatible visual field defects detected by automated static perimetry (Humphrey Visual Field Analyzer 30-2; Humphrey Instruments, San Leandro, California, USA) in one or both eyes. This study included patients with primary open angle glaucoma (POAG), primary angle closure glaucoma (PACG) and secondary glaucoma (SG). The exclusion criteria were as follows: (1) any other coexisting ocular condition that could impair visual function (eg, a visually significant cataract, retinal or neural pathology); (2) incisional ocular surgery in the past 3 months or laser treatment in the past 1 month; (3) current use of a medicine that might cause psychological disturbance, such as oral β-blockers; and (4) disability in a visual field test due to cognitive impairment.

The study was approved by the ethics committee of the hospital and was conducted according to the tenets of the Declaration of Helsinki. All participants gave their written informed consent. The data were labelled with serial numbers and analysed in a manner that protected patient privacy.

Clinical assessment {#s2b}
-------------------

All patients underwent a complete ophthalmologic examination including best-corrected visual acuity (BCVA), slit lamp biomicroscopy, tonometry, indirect ophthalmoscopy and visual field examination. BCVA was evaluated with Snellen equivalents, based on a standard refraction and testing protocol at a starting distance of 5 m. Intraocular pressure was measured using a Goldmann applanation tonometer (Haag-Streit 900; Haag Streit, Koeniz, Switzerland). Visual field analysis was performed with automated perimetry (Humphrey Instruments) using a 30-2 threshold program (HFA30-2) with the SITA Standard strategy. The mean deviation (MD) in the last HFA30-2 taken within 3 months of enrolment in this study was used to evaluate visual field loss.

General information including age, gender, educational level, living status and marital status, together with clinical information including the duration of glaucoma, type of glaucoma, length of membership of the SGC, glaucoma medication, previous laser treatment and previous surgical treatment were all recorded on a checklist.

Three questionnaires were administered to all subjects: a glaucoma comprehension questionnaire, a Chinese version of the Hospital Anxiety and Depression Scale (HADS), and the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). The subjects were requested to answer the questionnaire by themselves. The research staff explained the questionnaire to them and provided assistance when required. For participants who could not read due to poor eyesight, a research staff member read the questionnaire to them in a neutral and uniform manner and recorded their choices.

Evaluation of comprehension and understanding of glaucoma {#s2c}
---------------------------------------------------------

The glaucoma comprehension questionnaire consisted of 20 questions pertaining to three categories: the level of knowledge about glaucoma, compliance with medication usage and follow-up, and life style and habits. Answers to each question were scored, and the scores were summed for each section (0--12, 0--12 and 0--7, respectively) and as a total (0--31). Higher scores meant better understanding of glaucoma. This questionnaire was introduced and used in our previous study and published with it.[@R21]

Evaluation of psychological disturbance {#s2d}
---------------------------------------

The HADS questionnaire was developed by Zigmond and Snaith[@R23] to identify and quantify the two most common forms of psychological disturbance in physically ill patients: anxiety and depression. The original HADS was translated into Chinese Mandarin and has been validated in many studies.[@R24] [@R25] The HADS scale contains 14 questions graded on a four-point Likert scale (0--3). It consists of two subscales: HADS-anxiety (HADS-A) and HADS-depression (HADS-D). In each of the seven-item subscales, the minimum sum score is 0 and the maximum is 21. Higher scores indicate a higher level of depression and anxiety. In this study, patients with scores above 10 on the HADS-A and HADS-D were diagnosed as having anxiety and depression, respectively.[@R4] [@R7]

25-item National Eye Institute Visual Function Questionnaire {#s2e}
------------------------------------------------------------

The NEI VFQ-25 is a vision-related QoL instrument for patients, and the present study used the Chinese version of NEI VFQ-25 with an additional question.[@R26] [@R27] Since the response rate of item no. 14 was shown to be rather low in the Chinese population,[@R26] according to the instructions in the manual we chose item A8 from the NEI VFQ-39 to serve as an appendix to item no. 14. If the statistical analysis showed a low response rate for item no. 14, the results of the appendix would be used to alleviate the impact of a high miss rate for item no. 14 on the validity and reliability of the entire questionnaire.

Twelve subscales were included in the questionnaire: general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, colour vision and peripheral vision. Guidelines published by the NEI were followed in calculating the scale conversions and subscale scores. The subscales were scored on a range from 0 to 100. Higher NEI VFQ-25 scores indicated better QoL and less impairment.

Statistical analysis {#s2f}
--------------------

Data were analysed using SPSS for Windows, V.17.0 (SPSS, Chicago, Illinois, USA). The mean scores and SDs together with the range of the scores were calculated for each subscale and composite score of the glaucoma comprehension questionnaire, HADS and NEI VFQ-25. To determine the relationship between comprehension and HADS and between comprehension and NEI VFQ-25, multiple linear regression analysis was carried out with HADS and NEI VFQ-25 subscores as dependent variables and cognitive level as the independent variable, adjusted with or without demographic and clinical features. For the comparison between different levels of comprehension, three categories were formed based on the scores: low (0--18), moderate (19--25) and high (26--31). ANOVA and the Bonferroni test were used to detect differences. We divided the samples into 10 dB cohorts of the MD of the HFA30-2 test. The vision level of eyes that could not be examined by the HFA30-2 test because of poor visual function was assigned an MD value of −34.0 dB. For statistical analysis, vision levels of counting fingers, hand motion, light perception and no light perception were assigned visual acuity values of 1/200, 0.5/200, 0.25/200 and 0.125/200, respectively, and visual acuity was converted into a logarithm of minimum angular resolution (logMAR) visual acuity. A p value of \<0.05 was considered statistically significant.

Results {#s3}
=======

A total of 508 patients were enrolled in this study; as eight patients were excluded because of incomplete data, 500 patients with glaucoma were chosen as study participants. The proportion of valid data was 98.43%. [Table 1](#BMJOPEN2013004632TB1){ref-type="table"} shows the demographic characteristics of these subjects. The sample consisted of 266 males and 234 females. The mean age of the included subjects was 56.46±17.22 years and 92.6% had reached a middle school or higher educational level. Most (93.8%) of the subjects were living with family, and 87.4% were married. The mean duration of glaucoma for all subjects was 4.64±6.30 years; 54.2% had POAG, 37.2% had PACG and 8.6% had SG. Regarding treatment, 85.4% had one or more types of medication, 15.8% had undergone laser treatment, and 44.8% had undergone surgical treatment.

###### 

Sociodemographic and clinical characteristics of subjects

  Variable                         Mean±SD, range                 N=500
  -------------------------------- ------------------------------ -------
  Age, years                       56.46±17.22 (18--91)           
   18--40                                                         96
   41--60                                                         148
   \>60                                                           256
  Gender                                                          
   Male                                                           266
   Female                                                         234
  Educational level                                               
   Primary school                                                 37
   Middle school                                                  260
   University and above                                           203
  Living status                                                   
   Living alone                                                   31
   Living with family                                             469
  Marital status                                                  
   Unmarried                                                      45
   Married                                                        437
   Divorced                                                       2
   Single                                                         16
  Duration of glaucoma, years      4.64±6.30 (0.10--37.00)        
   \<1                                                            132
   1--5                                                           203
   \>5                                                            165
  Type of glaucoma                                                
   POAG                                                           271
   PACG                                                           186
   SG                                                             43
  Medication                                                      
   0                                                              73
   1 type                                                         174
   2 types                                                        166
   3 or more types                                                87
  Laser treatment                                                 
   No                                                             421
   Yes                                                            79
  Surgical treatment                                              
   No                                                             276
   Yes                                                            224
  SGC member                                                      
   No                                                             319
   Yes                                                            181
  BCVA of better-seeing eye        0.21±0.34 (−1.30 to 2.60)      
   \>20/40                                                        343
   20/200--20/40                                                  140
   \<20/200                                                       17
  BCVA of worse-seeing eye         0.80±0.94 (0.18--3.20)         
   \>20/40                                                        176
   20/200--20/40                                                  183
   \<20/200                                                       141
  Lower IOP in both eyes, mm Hg    15.93±5.33 (5.00--53.70)       
   \<18                                                           346
   18--30                                                         141
   \>30                                                           13
  Higher IOP in both eyes, mm Hg   20.65±9.43 (7.00--65.00)       
   \<18                                                           225
   18--30                                                         206
   \>30                                                           69
  MD of less-damaged eye, dB       −7.73±6.27 (−30.52 to 2.70)    
   \>−10                                                          370
   −10 to −20                                                     97
   \<−20                                                          33
  MD of most-damaged eye, dB       −15.01±9.40 (−34.00 to 0.70)   
   \>−10                                                          197
   −10 to −20                                                     145
   \<−20                                                          158

BCVA, best corrected visual acuity; IOP, intraocular pressure; MD, mean deviation; PACG, primary angle closure glaucoma; POAG, primary open angle glaucoma; SG, secondary glaucoma; SGC, Shanghai Glaucoma Club.

Mean scores for glaucoma comprehension, HADS and vision-related QoL {#s3a}
-------------------------------------------------------------------

The mean score of total glaucoma comprehension was 21.30±5.78. For the subgroups, it was 7.30±3.27 for knowledge of glaucoma, 9.21±2.10 for compliance, and 4.79±1.48 for habits.

The mean scores of total HADS, HADS-A and HADS-D were 13.41±6.59, 6.12±3.64 and 7.29±4.18, respectively. The prevalence of patients with glaucoma experiencing anxiety and depression was 11.2% and 26.0%, respectively.

For NEI VFQ-25 subscales, the scores ranged from 20.01 for driving to 87.60 for colour vision, and the composite score was 70.60±15.38. Since the driving subscale had a high rate of missing data (350/500, 70.0%), we omitted this subscale in the calculation of the composite score and in further analysis, as suggested by previous research (see [table 2](#BMJOPEN2013004632TB2){ref-type="table"}).

###### 

Scores for each subscale and total scale of the comprehension questionnaire, HADS and NEI VFQ-25 in all subjects

  Subscale                      N     Mean    SD      Range          Rank
  ----------------------------- ----- ------- ------- -------------- ------
  Comprehension questionnaire                                        
   Knowledge of glaucoma        500   7.30    3.27    0--12          2
   Compliance                   500   9.21    2.10    2--12          1
   Habits                       500   4.79    1.48    0--7           3
   Total comprehension          500   21.30   5.78    6--31          --
  HADS questionnaire                                                 
   HADS-A                       500   6.12    3.64    0--18          2
   HADS-D                       500   7.29    4.18    0--18          1
   HADS                         500   13.41   6.59    0--32          --
  NEI VFQ-25 questionnaire                                           
   General health               500   66.58   15.48   0--100         7
   General vision               500   52.41   18.80   0--100         11
   Ocular pain                  500   66.58   18.59   12.5--100      7
   Near activity                500   70.80   26.57   0--100         5
   Distance activity            500   72.40   26.15   0--100         4
   Social function              500   86.75   19.82   0--100         2
   Mental health                500   64.46   19.97   6.25--100      9
   Role difficulties            500   54.63   25.00   0--100         10
   Dependency                   500   68.95   24.78   0--100         6
   Driving                      150   20.01   34.46   0--100         12
   Colour vision                500   87.60   22.96   0--100         1
   Peripheral vision            500   84.55   19.83   0--100         3
   Composite score              500   70.60   15.38   16.40--97.16   --

HADS, Hospital Anxiety and Depression Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.

Regression analysis of psychological disturbance and vision-related QoL by glaucoma comprehension {#s3b}
-------------------------------------------------------------------------------------------------

The analyses showed that many of the variables such as age, gender, educational level, visual acuity, severity and duration of glaucoma showed relationships with HADS scores and NEI VFQ-25 scores, so other variables were controlled in order to investigate the relationship between glaucoma comprehension and HADS and NEI VFQ-25. [Table 3](#BMJOPEN2013004632TB3){ref-type="table"} showed the complete result with or without adjustments for other variables. Total glaucoma comprehension and its three subtypes (knowledge of glaucoma, compliance and habits) were negatively correlated with HADS-D and total HADS. The higher the level of comprehension, the lower the level of depression. However, the level of comprehension showed no correlation with HADS-A. For NEI VFQ-25, the level of comprehension was positively correlated with general vision, near activity, distance activity, social function, colour vision and the composite score. The higher the level of comprehension, the higher the scores for these items. Understanding of glaucoma was not correlated with general health, ocular pain, mental health, role difficulties, dependency or peripheral vision.

###### 

Multivariate linear regression of subscales of HADS and NEI VFQ-25 according to the comprehension of patients with glaucoma

                      Knowledge of glaucoma   Compliance    Habits       Total comprehension                                           
  ------------------- ----------------------- ------------- ------------ --------------------- ------------ ------------- ------------ -------------
  HADS-A                                                                                                                               
   Model 1            −0.0 (0.0)              0.471         −0.1 (0.1)   0.238                 0.0 (0.1)    0.986         −0.0 (0.0)   0.405
   Model 2            −0.1 (0.1)              0.168         −0.2 (0.1)   0.058                 −0.2 (0.1)   0.174         −0.1 (0.0)   **0.040**
   Model 3            −0.1 (0.1)              0.244         −0.1 (0.1)   0.085                 −0.1 (0.1)   0.258         −0.1 (0.0)   0.074
  HADS-D                                                                                                                               
   Model 1            −0.5 (0.1)              **\<0.001**   −0.7 (0.1)   **\<0.001**           −1.1 (0.1)   **\<0.001**   −0.3 (0.0)   **\<0.001**
   Model 2            −0.3 (0.1)              **\<0.001**   −0.4 (0.1)   **\<0.001**           −0.7 (0.1)   **\<0.001**   −0.2 (0.0)   **\<0.001**
   Model 3            −0.2 (0.1)              **\<0.001**   −0.3 (0.1)   **\<0.001**           −0.7 (0.1)   **\<0.001**   −0.2 (0.0)   **\<0.001**
  HADS                                                                                                                                 
   Model 1            −0.5 (0.1)              **\<0.001**   −0.8 (0.1)   **\<0.001**           −1.1 (0.2)   **\<0.001**   −0.4 (0.0)   **\<0.001**
   Model 2            −0.3 (0.1)              **0.002**     −0.5 (0.2)   **\<0.001**           −0.9 (0.2)   **\<0.001**   −0.3 (0.1)   **\<0.001**
   Model 3            −0.3 (0.1)              **0.008**     −0.5 (0.1)   **\<0.001**           −0.8 (0.2)   **\<0.001**   −0.3 (0.1)   **\<0.001**
  General health                                                                                                                       
   Model 1            0.3 (0.2)               0.154         0.5 (0.3)    0.135                 0.3 (0.5)    0.500         0.2 (0.1)    0.128
   Model 2            0.3 (0.3)               0.259         0.4 (0.4)    0.242                 0.5 (0.5)    0.358         0.2 (0.2)    0.145
   Model 3            0.2 (0.3)               0.463         0.3 (0.4)    0.355                 0.3 (0.5)    0.542         0.2 (0.2)    0.306
  General vision                                                                                                                       
   Model 1            0.9 (0.3)               **\<0.001**   1.5 (0.4)    **\<0.001**           1.6 (0.6)    **0.004**     0.6 (0.1)    **\<0.001**
   Model 2            1.0 (0.3)               **0.001**     1.4 (0.4)    **\<0.001**           1.6 (0.6)    **0.007**     0.8 (0.2)    **\<0.001**
   Model 3            0.7 (0.3)               **0.012**     1.2 (0.4)    **0.002**             1.2 (0.6)    **0.030**     0.6 (0.2)    **\<0.001**
  Ocular pain                                                                                                                          
   Model 1            0.1 (0.3)               0.597         0.1 (0.4)    0.859                 0.1 (0.6)    0.872         0.1 (0.1)    0.685
   Model 2            0.4 (0.3)               0.222         0.1 (0.5)    0.883                 0.5 (0.6)    0.428         0.2 (0.2)    0.303
   Model 3            0.2 (0.3)               0.590         −0.1 (0.4)   0.798                 0.3 (0.6)    0.662         0.1 (0.2)    0.732
  Near activity                                                                                                                        
   Model 1            2.0 (0.4)               **\<0.001**   3.0 (0.6)    **\<0.001**           3.1 (0.8)    **\<0.001**   1.3 (0.2)    **\<0.001**
   Model 2            1.5 (0.4)               **\<0.001**   2.2 (0.6)    **\<0.001**           2.5 (0.9)    **0.004**     1.2 (0.3)    **\<0.001**
   Model 3            1.1 (0.4)               **0.006**     1.8 (0.6)    **0.001**             1.9 (0.8)    **0.017**     0.9 (0.2)    **\<0.001**
  Distance activity                                                                                                                    
   Model 1            1.7 (0.3)               **\<0.001**   2.7 (0.5)    **\<0.001**           3.5 (0.8)    **\<0.001**   1.1 (0.2)    **\<0.001**
   Model 2            1.3 (0.4)               **0.003**     2.1 (0.6)    **\<0.001**           3.3 (0.9)    **\<0.001**   1.2 (0.3)    **\<0.001**
   Model 3            0.9 (0.4)               **0.030**     1.7 (0.5)    **0.002**             2.6 (0.8)    **\<0.001**   0.9 (0.2)    **\<0.001**
  Social function                                                                                                                      
   Model 1            0.5 (0.3)               0.067         1.0 (0.4)    **0.021**             1.1 (0.6)    0.069         0.4 (0.2)    **0.019**
   Model 2            0.7 (0.3)               **0.049**     1.2 (0.5)    **0.013**             1.8 (0.7)    **0.008**     0.6 (0.2)    **0.002**
   Model 3            0.4 (0.3)               0.205         0.9 (0.4)    **0.035**             1.3 (0.6)    **0.032**     0.4 (0.2)    **0.020**
  Mental health                                                                                                                        
   Model 1            0.1 (0.3)               0.853         −0.1 (0.4)   0.834                 −0.1 (0.6)   0.847         −0.0 (0.2)   0.984
   Model 2            0.3 (0.3)               0.337         0.1 (0.5)    0.766                 0.9 (0.7)    0.177         0.2 (0.2)    0.267
   Model 3            0.2 (0.3)               0.617         −0.0 (0.5)   0.956                 0.6 (0.6)    0.350         0.1 (0.2)    0.577
  Role difficulties                                                                                                                    
   Model 1            0.0 (0.3)               0.985         −0.1 (0.5)   0.880                 −0.4 (0.8)   0.622         −0.0 (0.2)   0.865
   Model 2            0.8 (0.4)               0.066         0.7 (0.6)    0.266                 0.7 (0.9)    0.387         0.5 (0.3)    0.066
   Model 3            0.5 (0.4)               0.200         0.4 (0.6)    0.451                 0.3 (0.8)    0.676         0.3 (0.3)    0.225
  Dependency                                                                                                                           
   Model 1            0.6 (0.3)               0.074         −0.2 (0.5)   0.773                 0.4 (0.7)    0.636         0.2 (0.2)    0.304
   Model 2            0.5 (0.4)               0.217         −0.7 (0.6)   0.253                 0.7 (0.8)    0.397         0.1 (0.3)    0.618
   Model 3            0.5 (0.4)               0.288         −0.7 (0.6)   0.230                 0.7 (0.9)    0.406         0.1 (0.3)    0.716
  Colour vision                                                                                                                        
   Model 1            0.8 (0.3)               **0.006**     1.3 (0.5)    **0.007**             1.9 (0.7)    **0.006**     0.6 (0.2)    **0.001**
   Model 2            0.9 (0.4)               **0.024**     1.3 (0.6)    **0.016**             2.4 (0.8)    **0.002**     0.8 (0.2)    **\<0.001**
   Model 3            0.7 (0.4)               0.080         1.1 (0.5)    **0.036**             2.1 (0.8)    **0.007**     0.7 (0.2)    **0.005**
  Peripheral vision                                                                                                                    
   Model 1            −0.2 (0.3)              0.489         0.0 (0.4)    0.965                 −0.2 (0.6)   0.723         −0.1 (0.2)   0.641
   Model 2            0.3 (0.3)               0.373         0.6 (0.5)    0.189                 1.2 (0.7)    0.066         0.3 (0.2)    0.098
   Model 3            0.0 (0.3)               0.885         0.3 (0.4)    0.417                 0.8 (0.6)    0.215         0.2 (0.2)    0.414
  Composite score                                                                                                                      
   Model 1            0.6 (0.2)               **0.003**     0.9 (0.3)    **0.008**             1.0 (0.5)    **0.032**     0.4 (0.1)    **0.002**
   Model 2            0.7 (0.3)               **0.005**     0.8 (0.3)    **0.016**             1.4 (0.5)    **0.004**     0.5 (0.1)    **\<0.001**
   Model 3            0.5 (0.2)               **0.045**     0.6 (0.3)    0.051                 1.1 (0.5)    **0.019**     0.4 (0.1)    **0.006**

Comprehension of glaucoma, compliance, habits and total comprehension were independent variables in the models. Model 1: crude; model 2: adjustment for age, gender, educational level, living status, marital status, duration of glaucoma, type of glaucoma, medication, past laser treatment and past surgical treatment; model 3: further adjustment for best corrected visual acuity of worse-seeing eye, higher intraocular pressure in both eyes, and mean deviation of visual field in worse-seeing eye based on model 2.

HADS, Hospital Anxiety and Depression Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.

Comparison of depression and the NEI VFQ-25 composite score by different levels of glaucoma comprehension {#s3c}
---------------------------------------------------------------------------------------------------------

As the level of comprehension increased from low to high, the scores of HADS-D (p\<0.001) and total HADS (p\<0.001) decreased significantly (p\<0.001), while the subscores of general vision (p\<0.001), near activity (p\<0.001), far activity (p\<0.001) and the composite score (p\<0.05) of NEI VFQ-25 increased dramatically ([figures 1](#BMJOPEN2013004632F1){ref-type="fig"} and [2](#BMJOPEN2013004632F2){ref-type="fig"}). The subtypes of comprehension were also categorised into low, moderate and high levels: knowledge of glaucoma (0--7, 8--10, 11--12), compliance (0--7, 8--10, 11--12) and habits (0--4, 5, 6--7). The differences among the three levels, between low versus moderate, between low versus high, and between moderate versus high, were analysed. Only compliance had a significant influence on the level of depression of the groups being compared. Knowledge and habits had a significantly different effect on depression in the low versus moderate and low versus high groups. Only habits had a statistically significant effect on the composite score in the low versus moderate groups ([table 4](#BMJOPEN2013004632TB4){ref-type="table"}).

###### 

Comparison of the HADS-D score and NEI VFQ-25 composite score by different levels of the subtypes of comprehension

  Subtype of comprehension   N     HADS-D      p Value     p1 Value    p2 Value    p3 Value    NEI VFQ-25 composite score   p Value     p1 Value    p2 Value   p3 Value
  -------------------------- ----- ----------- ----------- ----------- ----------- ----------- ---------------------------- ----------- ----------- ---------- ----------
  Knowledge of glaucoma                        **0.000**   **0.000**   **0.000**   1.000                                    0.292       1.000       0.363      1.000
   Low                       234   9.06±4.00                                                   69.64±15.85                                                     
   Moderate                  169   5.89±3.72                                                   70.83±15.23                                                     
   High                      97    5.48±3.67                                                   72.52±14.40                                                     
  Compliance                                   **0.000**   **0.001**   **0.000**   **0.000**                                0.139       0.527       0.142      1.000
   Low                       105   9.31±4.11                                                   68.21±15.59                                                     
   Moderate                  230   7.61±4.18                                                   70.66±14.92                                                     
   High                      165   5.56±3.52                                                   72.02±15.77                                                     
  Habits                                       **0.000**   **0.000**   **0.000**   0.327                                    **0.001**   **0.000**   0.066      0.276
   Low                       175   9.38±4.18                                                   67.40±16.54                                                     
   Moderate                  140   6.56±3.81                                                   73.95±13.82                                                     
   High                      185   5.86±3.65                                                   71.08±14.82                                                     

p Value: ANOVA; further compared by Bonferroni: p1: low versus moderate; p2: low versus high; p3: moderate versus high.

HADS-D, Hospital Anxiety and Depression Scale-Depression; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.

![The association between level of comprehension and the subscores of the Hospital Anxiety and Depression Scale (HADS), HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) in Chinese patients with glaucoma. As the level of comprehension increased, the scores of HADS-D and total HADS decreased significantly (F=65.371, p\<0.001; F=25.302, p\<0.001, respectively), while the change in HADS-A was not significant (F=0.638, p=0.529).](bmjopen2013004632f01){#BMJOPEN2013004632F1}

![The association between level of comprehension and four of the subscores of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) in Chinese patients with glaucoma. As the level of comprehension increased, the subscores of general vision (F=8.372, p\<0.001), near activity (F=16.607, p\<0.001), far activity (F=12.884, p\<0.001) and the NEI VFQ-25 composite score (F=3.821, p\<0.05) increased dramatically.](bmjopen2013004632f02){#BMJOPEN2013004632F2}

Factors influencing the comprehension of patients with glaucoma {#s3d}
---------------------------------------------------------------

The level of comprehension of patients with glaucoma was positively related to the duration of their glaucoma. The scores of all subtypes (knowledge of glaucoma, compliance and habits) and of total comprehension significantly increased as the duration of glaucoma increased (F=46.160, p\<0.001). The comprehension score of SGC members was 25.34±3.73, much higher than that of non-SGC members, which was 19.01±5.48 (p\<0.001). Being an SGC member had a significant effect on the level of comprehension of patients with glaucoma. The longer the membership of the SGC, the higher the comprehension score (F=39.676, p\<0.001).

Discussion {#s4}
==========

This study demonstrated that the level of understanding of glaucoma is an independent factor for psychological disturbance and QoL among patients with glaucoma. The level of comprehension is negatively correlated with depression and positively correlated with QoL, which means the higher the level of comprehension, the lower the level of depression and the higher the QoL. Among the subtypes of comprehension, habits significantly influenced depression and the QoL composite score, while knowledge of glaucoma and compliance only influenced depression.

Patients with glaucoma may experience lack of glaucoma knowledge and psychological disturbance.[@R4] [@R21] However, few studies have investigated the relationship between glaucoma comprehension and psychological disturbance. Stryker *et al*[@R28] studied the relationship between adherence and psychological status and found that non-adherent participants were more fatalistic and less optimistic than adherent participants. However, the authors only examined adherence. In this study, we focused on patients with glaucoma and studied glaucoma comprehension, psychological disturbance and relationships. The glaucoma comprehension questionnaire showed a mean score of total comprehension of 21.30±5.78 (ranging from 6 to 31). A total of 178 cases (35.6%) belonged to the group with a low level of comprehension. As the level of comprehension increased, the subscores of HADS-D and HADS significantly decreased (from 9.74 to 5.03 and from 15.88 to 10.90, respectively). Our study suggests that improving the comprehension of patients with glaucoma, for instance by educating them about the slow progression of glaucoma and the effectiveness of treatments to delay progression, could alleviate their psychological disturbance, especially depression.

In recent years, increasing attention has been paid to QoL. Because a human being is a whole unit, for lifelong chronic diseases such as glaucoma, we cannot focus only on the eyes and neglect the rest of the body. Glaucoma may affect a patient\'s QoL in several ways, through the psychological effects of diagnosis (eg, anxiety, depression, fear of blindness, fear of effects on other family members), the visual effects of glaucoma (eg, decreased visual field), the potential side effects of treatment (medical or surgical), and the financial effects (eg, cost of visits and treatment, loss of income because of absenteeism from work). The vision-related QoL of patients with glaucoma in different countries can be compared by using NEI VFQ-25. The composite score of Mandarin Chinese subjects in our study was 70.6±15.4, slightly higher than that of Taiwan Chinese (69.2±20.4)[@R29] and Japanese participants (69.8±1.9),[@R30] but lower than that of Greek (81.7±14.7)[@R31] and Nigerian individuals (85.2±16.1).[@R32] This indicates that, in China, patients with glaucoma have a moderate vision-related QoL. Moreover, the extent of visual field damage could influence QoL. In the present study, the NEI VFQ-25 composite scores in the mild, moderate and severe groups were 76.1±12.8, 69.5±14.1 and 64.6±17.2, respectively. In a Nigerian population, the corresponding scores were 92.0±6.8, 89.3±10.4 and 74.3±21.1.[@R32] A study in Belgium found that the global NEI VFQ-25 score dropped from 90.7±8.1 to 86.1±8.7 to 71.5±19.3 in early, moderate and advanced POAG groups.[@R33] These findings demonstrate that vision-related QoL decreases with visual field progression. In the current study, after different levels were adjusted for variables, the extent of comprehension was always an independent factor positively related to the NEI VFQ-25 composite score (β=0.4, p=0.002; β=0.5, p\<0.001; β=0.4, p=0.006). This score increased from 68.52 in the low comprehension group to 73.20 in the high comprehension group. Our results suggest that early diagnosis and intervention is essential for patients with glaucoma, and that educating patients can help them establish good habits that might benefit their QoL.

After being told of their glaucoma diagnosis, 34% of patients reported at least a moderate fear of blindness.[@R2] It has been suggested that more attention should be given to reducing fear of blindness in patients with glaucoma at diagnosis and over time.[@R2] Our results showed that glaucoma comprehension was lowest at the early stage of diagnosis. Also, habits had the lowest score among the three subtypes, which significantly correlated with both HADS-D and the NEI VFQ-25 composite score. Thus, instead of merely informing the patients of their diagnosis, clinicians should enhance patients' knowledge of this disease and thereby reduce undue worry and concern over the glaucoma diagnosis,[@R34] and help them to establish appropriate habits. Various styles of health education could have a positive effect on relieving the fear of patients.[@R34] In existence for over 17 years, the SGC is a successful model for the education of patients with glaucoma.[@R22] Our previous report and the current study demonstrated significant differences in basic glaucoma knowledge between SGC members and general patients with glaucoma; SGC members had much better comprehension of glaucoma and self-management.[@R21] It may be that people who joined the SGC had a more positive outlook on life and were more motivated to manage their condition. Nevertheless, in the absence of other methods, the SGC might be an effective model for improving patients' knowledge of the disease and compliance with treatment.

Our findings also provided epidemiological data on anxiety and depression in Chinese patients with glaucoma. The prevalence of anxiety in Chinese patients with glaucoma (11.2%) was comparable to that of Japan (13.0%)[@R4] and Turkey (9.6--14.0%).[@R6] [@R35] However, the prevalence of depression in our study (26.0%) was higher than that of Japan (10.9%)[@R4] and Turkey (24.7%),[@R35] and lower than that found in another study from Turkey (57.0%).[@R6]

This study was an initial exploration of the psychological status and QoL of Chinese patients with glaucoma and the potential ways to improve them. Caution should be exercised when interpreting the findings because of a number of limitations. First, this was a cross-sectional rather than a longitudinal study. Although the conclusions drawn were based on multivariate linear regression with adjustment for possible confounding factors, further large-scale studies with long-term follow-up should be performed to confirm these findings of associations between glaucoma comprehension, depression and QoL. Second, all patients in this study were recruited from a single academic eye institute, and all were of Chinese Han ethnicity. This might have caused selection bias and our results might not be generalisable to the entire adult Chinese population with glaucoma. Third, to further investigate the influence of comprehension, we categorised the comprehension scores into three levels. This artificial classification might have led to bias. In addition, although this study examined several factors that might affect psychological status and QoL, by no means were all potential variables included. In an effort to address these limitations, the study covered a relatively large, homogeneous sample with a broad age range and applied rigorous quality control procedures to ensure high participant response rates and quality data.

In summary, for a typical physical disease such as glaucoma, patients' comprehension and understanding of their condition might be independently associated with psychological disturbance and vision-related QoL. Comprehension of glaucoma could be improved by education, which would help patients alleviate their psychological disturbance and enhance their vision-related QoL. Doctors should also pay attention to the patients' comprehension of glaucoma through better education and communication with patients regarding their disease and effective guidance over the course of their treatment.
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